View Financial HealthTranslational Development Acquisition 배당 및 자사주 매입배당 기준 점검 0/6Translational Development Acquisition 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-68.1%자사주 매입 수익률총 주주 수익률-68.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to US$11.50, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 40x in the Capital Markets industry in the US. Total returns to shareholders of 11% over the past year.공시 • May 29Prologium Holdings Inc. agreed to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction.Prologium Holdings Inc. ntered into a definitive agreement to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction on May 27, 2026. The transaction values Prologium at approximately $3.8 billion on a pre-money, net cash-free basis. Upon closing, ProLogium will own 92% of the combined company with SPAC & PIPE Investors owning 7%, and SPAC Sponsor owning 1%. Upon completion, the combined company is expected to be named ProLogium Technology and to be listed on Nasdaq under the ticker symbol "PRLG". As part of the transaction, the post-closing board shall consist of nine directors whom one individual is expected to be Michael Hoffman. The consummation of the transaction is conditioned upon, among other things: (i) approval for listing of Prologium Class A Ordinary Shares and warrants contemplated to be listed pursuant to the Business Combination Agreement on Nasdaq; (ii) the absence of any governmental order enjoining, restraining, prohibiting or otherwise making illegal the consummation of the Business Combination; (iii) receipt of the required approval by TDAC shareholders; (iv) receipt of the required approval by Prologium shareholders; (v) the effectiveness of the registration statement to be filed by Prologium under the Securities Act of 1933, as amended; (vi) the Second Merger Surviving Company, as successor to TDAC, having at least $5,000,001 of net tangible assets after the consummation of the Business Combination and the closing of any TDAC shareholder redemptions; (vii) completion of the Recapitalization in accordance with the Business Combination Agreement; (viii) lock-up agreement; (ix) registration rights agreement; and (x) Available Cash, as defined in the Business Combination Agreement, being greater than or equal to $250 million. The boards of directors of both ProLogium and TDAC have approved the Transaction, which is expected to close in the second half of 2026. Venable LLP acted as legal advisor for Translational Development Acquisition Corp. Sullivan & Cromwell LLP acted as legal advisor for Prologium Holdings Inc. BTIG, LLC acted as financial advisor for Translational Development Acquisition Corp. Cohen & Company Capital Markets, LLC acted as financial advisor for Prologium Holdings Inc. LCS & Partners acted as legal advisor for Prologium Holdings Inc.Board Change • May 26High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Michael M. Hoffman is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Dec 24Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million.Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 15,000,000 Price\Range: $10 Discount Per Security: $0.55 Transaction Features: Blank Check Blind Pool Company지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 TDAC.U 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: TDAC.U 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Translational Development Acquisition 배당 수익률 vs 시장TDAC.U의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (TDAC.U)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.1%업계 평균 (Capital Markets)2.0%분석가 예측 (TDAC.U) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 TDAC.U 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 TDAC.U 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 TDAC.U 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: TDAC.U 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/05 23:42종가2026/07/02 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Translational Development Acquisition Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to US$11.50, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 40x in the Capital Markets industry in the US. Total returns to shareholders of 11% over the past year.
공시 • May 29Prologium Holdings Inc. agreed to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction.Prologium Holdings Inc. ntered into a definitive agreement to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction on May 27, 2026. The transaction values Prologium at approximately $3.8 billion on a pre-money, net cash-free basis. Upon closing, ProLogium will own 92% of the combined company with SPAC & PIPE Investors owning 7%, and SPAC Sponsor owning 1%. Upon completion, the combined company is expected to be named ProLogium Technology and to be listed on Nasdaq under the ticker symbol "PRLG". As part of the transaction, the post-closing board shall consist of nine directors whom one individual is expected to be Michael Hoffman. The consummation of the transaction is conditioned upon, among other things: (i) approval for listing of Prologium Class A Ordinary Shares and warrants contemplated to be listed pursuant to the Business Combination Agreement on Nasdaq; (ii) the absence of any governmental order enjoining, restraining, prohibiting or otherwise making illegal the consummation of the Business Combination; (iii) receipt of the required approval by TDAC shareholders; (iv) receipt of the required approval by Prologium shareholders; (v) the effectiveness of the registration statement to be filed by Prologium under the Securities Act of 1933, as amended; (vi) the Second Merger Surviving Company, as successor to TDAC, having at least $5,000,001 of net tangible assets after the consummation of the Business Combination and the closing of any TDAC shareholder redemptions; (vii) completion of the Recapitalization in accordance with the Business Combination Agreement; (viii) lock-up agreement; (ix) registration rights agreement; and (x) Available Cash, as defined in the Business Combination Agreement, being greater than or equal to $250 million. The boards of directors of both ProLogium and TDAC have approved the Transaction, which is expected to close in the second half of 2026. Venable LLP acted as legal advisor for Translational Development Acquisition Corp. Sullivan & Cromwell LLP acted as legal advisor for Prologium Holdings Inc. BTIG, LLC acted as financial advisor for Translational Development Acquisition Corp. Cohen & Company Capital Markets, LLC acted as financial advisor for Prologium Holdings Inc. LCS & Partners acted as legal advisor for Prologium Holdings Inc.
Board Change • May 26High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Michael M. Hoffman is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Dec 24Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million.Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 15,000,000 Price\Range: $10 Discount Per Security: $0.55 Transaction Features: Blank Check Blind Pool Company